Nanollose has narrowed its microbial cellulose scale-up plan to one company-controlled Western Australian pilot facility, with all Stage 1 equipment ordered and paid for. The progress comes with a clear funding constraint: the ASX-listed biomaterials developer ended September with $758,000 in cash, equivalent to 1.41 quarters of funding at its current operating burn.
- Single Western Australian Pilot Facility replaces a planned larger demonstration line
- All Stage 1 equipment ordered and paid for, with final shipments expected within two months
- Laboratory process continues to show at least an 80% efficiency uplift over the fourth pilot method
- Stage 2 commissioning targeted for Q3 CY2027, subject to funding, premises and permits
- $758,000 cash balance and $538,000 quarterly operating outflow leave 1.41 quarters of estimated funding
Single pilot facility becomes Nanollose’s commercialisation bridge
Nanollose Limited (ASX:NC6) has simplified its route from laboratory process to commercial partnering, settling on a single company-controlled microbial cellulose Pilot Facility in Western Australia. The company says the revised pathway removes the need for a later, larger demonstration production line and should provide a shorter, less capital-intensive route to licensing, sale or joint venture discussions.
The strategy remains to support industrial-scale deployment through partners rather than build industrial production capacity itself. Equipment is being selected so data generated at the pilot site can be extrapolated to industrial scale, but the facility still depends on securing suitable premises, completing fit-out work and obtaining required permits.
Engineering team and process work move towards execution
The shift from planning to execution has been accompanied by an expanded engineering team. Senior consultants Peter Hillier and Dr Jacob Brown have joined Operations and Engineering Manager Danielle Nardini, bringing experience in process engineering, chemical manufacturing and the scale-up of emerging technologies. Their fees were partly reduced in exchange for options tied to Pilot Facility and market milestones, including design, costing and commissioning objectives.
Nanollose also reported that its improved laboratory process continues to deliver at least an 80% efficiency uplift over the method used for the fourth pilot production spin, alongside a more uniform product. Larger-volume local dewatering trials have been completed, while washing, dewatering and dissolution work continues to determine the equipment configuration and operating parameters needed at pilot scale.
Stage 1 is funded internally, but Stage 2 is conditional
All significant Stage 1 equipment has now been ordered and paid for, with several items already delivered and the remaining key pieces expected to ship over the following two months. The stage is intended to expand Nanollose’s in-house process development capability and produce the operating data required to finalise the larger Stage 2 configuration.
Nanollose has received 500 kilograms of microbial cellulose pellicles from supply partner HGB for vendor trials and laboratory work. Stage 2 is designed to produce microbial cellulose pulp at a volume the company believes can support multiple meaningful partner collaborations, with long-lead items expected to be ordered in November and commissioning targeted for Q3 CY2027. That timetable is expressly subject to funding, a suitable facility and permits.
Cash runway puts funding on the critical path
The company’s cash position is the sharper investor issue. Nanollose ended the September quarter with $758,000, down from $1.35 million at 30 June, after $538,000 of net operating cash outflows and $98,000 spent on property, plant and equipment. A further $44,000 came from option exercises, leaving estimated funding of 1.41 quarters at the reported operating cash-outflow rate.
Nanollose said it expects its operating outflows to remain broadly consistent, subject to the timing of research and development spending. It also expects funds from the exercise of in-the-money listed options expiring on 6 February 2027 and receipt of its R&D Tax Incentive in the current quarter. Those sources may extend the immediate runway, but the filing does not disclose a committed funding package for Stage 2, making November’s roadmap and the premises decision important tests of how quickly the plan can move from equipment procurement to operating proof.
Bottom Line?
The technical pathway is becoming more concrete, but Stage 2 timing now rests on cash generation, premises and permits as much as engineering progress.
Questions in the middle?
- How much funding will Nanollose require to complete Stage 2 and reach its Q3 CY2027 commissioning target?
- Will option exercises and the R&D Tax Incentive provide enough additional cash before larger facility and equipment costs arrive?
- Can the Stage 1 data and planned production volumes convert into binding licensing, sale or joint venture discussions?